{"transactions":[{"id":4628851,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-10-02T22:17:05.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":3378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1476707,"source":{"system":"sec-edgar","filing":"0001601830-26-000115","document":"wk-form4_1790979423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837016/000160183026000115/wk-form4_1790979423.xml","form_type":"4"}},{"id":717190,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:15:43.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":3747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1473329,"source":{"system":"sec-edgar","filing":"0001601830-26-000091","document":"wk-form4_1783026941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000091/wk-form4_1783026941.xml","form_type":"4"}},{"id":730037,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T20:32:08.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":88424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 136,981 shares of Class A common stock transferred from the Dean Y. Li GRAT on May 7, 2026."}],"balance_after":1469582,"source":{"system":"sec-edgar","filing":"0001601830-26-000083","document":"wk-form4_1782160325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000083/wk-form4_1782160325.xml","form_type":"4"}},{"id":10082,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T16:07:01.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":58207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029."}],"balance_after":58207,"derivative":{"exercise_price":113.15,"exercise_date":"2027-05-05","expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":58207},"source":{"system":"sec-edgar","filing":"0000310158-26-000133","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000133/form4.xml","form_type":"4"}},{"id":10081,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2026-05-07T16:07:01.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":19885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029."}],"balance_after":19885,"derivative":{"exercise_date":"2027-05-05","expiration_date":"2029-05-05","underlying":"Common Stock","underlying_shares":19885},"source":{"system":"sec-edgar","filing":"0000310158-26-000133","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000133/form4.xml","form_type":"4"}},{"id":10387,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2026-05-01T21:45:07.000Z","date":"2026-04-29","kind":"exercise","planned":false,"acquired":false,"shares":4722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028."}],"balance_after":9444,"derivative":{"exercise_date":"2026-04-29","expiration_date":"2028-04-29","underlying":"Common Stock","underlying_shares":4722},"source":{"system":"sec-edgar","filing":"0000310158-26-000088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000088/form4.xml","form_type":"4"}},{"id":10386,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-05-01T21:45:07.000Z","date":"2026-04-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":2326,"price":110.03,"value":255929.78,"ownership":{"direct":true},"balance_after":94431.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000088/form4.xml","form_type":"4"}},{"id":10385,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-05-01T21:45:07.000Z","date":"2026-04-29","kind":"exercise","planned":false,"acquired":true,"shares":4722,"price":110.03,"value":519561.66,"ownership":{"direct":true},"balance_after":96757.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000088/form4.xml","form_type":"4"}},{"id":818912,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-04-02T20:56:19.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":3268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1244177,"source":{"system":"sec-edgar","filing":"0001837016-26-000005","document":"wk-form4_1775163374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000183701626000005/wk-form4_1775163374.xml","form_type":"4"}},{"id":14335,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-02-10T21:04:14.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":10235,"price":117.5226,"value":1202843.811,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5200 to $117.5550, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote."}],"balance_after":92035.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000050/form4.xml","form_type":"4"}},{"id":14566,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-06T21:12:16.000Z","date":"2026-02-04","kind":"exercise","planned":false,"acquired":false,"shares":15087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. (\"Organon\") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the \"Form 10\"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021."}],"balance_after":0,"derivative":{"exercise_price":56.04,"exercise_date":"2019-05-04","expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":15087},"source":{"system":"sec-edgar","filing":"0000310158-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000036/form4.xml","form_type":"4"}},{"id":14565,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-02-06T21:12:16.000Z","date":"2026-02-04","kind":"sale","planned":false,"acquired":false,"shares":15087,"price":118.7661,"value":1791824.1507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.7200 to $118.8300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":102270.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000036/form4.xml","form_type":"4"}},{"id":14564,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-02-06T21:12:16.000Z","date":"2026-02-04","kind":"exercise","planned":false,"acquired":true,"shares":15087,"price":56.04,"value":845475.48,"ownership":{"direct":true},"balance_after":117357.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000036/form4.xml","form_type":"4"}},{"id":15073,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2026-01-28T21:09:26.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":20469,"price":107.4,"value":2198370.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":102270.05,"source":{"system":"sec-edgar","filing":"0000310158-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000016/form4.xml","form_type":"4"}},{"id":945695,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-06T22:47:45.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1240909,"source":{"system":"sec-edgar","filing":"0001837016-26-000003","document":"wk-form4_1767739662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000183701626000003/wk-form4_1767739662.xml","form_type":"4"}},{"id":1024062,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-03T20:27:37.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":1961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1238528,"source":{"system":"sec-edgar","filing":"0001837016-25-000005","document":"wk-form4_1759523254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000183701625000005/wk-form4_1759523254.xml","form_type":"4"}},{"id":1091851,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-03T19:30:26.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":1949,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1236567,"source":{"system":"sec-edgar","filing":"0001601830-25-000116","document":"wk-form4_1751571020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000116/wk-form4_1751571020.xml","form_type":"4"}},{"id":1103471,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T21:22:51.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":44031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":44031,"derivative":{"exercise_price":5.11,"expiration_date":"2035-06-18","underlying":"Class A Common Stock","underlying_shares":44031},"source":{"system":"sec-edgar","filing":"0001601830-25-000107","document":"wk-form4_1750713764.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000107/wk-form4_1750713764.xml","form_type":"4"}},{"id":1103470,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-23T21:22:51.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":22016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,132,815 shares of Class A common stock transferred from the Dean Y. Li GRAT on June 10, 2025."}],"balance_after":1234618,"source":{"system":"sec-edgar","filing":"0001601830-25-000107","document":"wk-form4_1750713764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000107/wk-form4_1750713764.xml","form_type":"4"}},{"id":24654,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T22:04:29.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":64481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028."}],"balance_after":64481,"derivative":{"exercise_price":84.71,"exercise_date":"2026-04-29","expiration_date":"2035-04-28","underlying":"Common Stock","underlying_shares":64481},"source":{"system":"sec-edgar","filing":"0001127602-25-013039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760225013039/form4.xml","form_type":"4"}},{"id":24653,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2025-05-01T22:04:29.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":14166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028."}],"balance_after":14166,"derivative":{"exercise_date":"2026-04-29","expiration_date":"2028-04-29","underlying":"Common Stock","underlying_shares":14166},"source":{"system":"sec-edgar","filing":"0001127602-25-013039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760225013039/form4.xml","form_type":"4"}},{"id":1178789,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-03T20:37:52.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":2268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":79618,"source":{"system":"sec-edgar","filing":"0001601830-25-000056","document":"wk-form4_1743712643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000056/wk-form4_1743712643.xml","form_type":"4"}},{"id":29620,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2025-01-29T23:19:34.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":32621,"price":97.94,"value":3194900.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":79592.15,"source":{"system":"sec-edgar","filing":"0001127602-25-002346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760225002346/form4.xml","form_type":"4"}},{"id":1309722,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-01-06T23:02:41.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":77350,"source":{"system":"sec-edgar","filing":"0001601830-25-000005","document":"wk-form4_1736204554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000005/wk-form4_1736204554.xml","form_type":"4"}},{"id":1390613,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-04T22:29:59.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":1925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":75703,"source":{"system":"sec-edgar","filing":"0001601830-24-000171","document":"wk-form4_1728080993.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000171/wk-form4_1728080993.xml","form_type":"4"}},{"id":1459305,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-07-03T20:40:06.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":73778,"source":{"system":"sec-edgar","filing":"0001601830-24-000099","document":"wk-form4_1720039199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000099/wk-form4_1720039199.xml","form_type":"4"}},{"id":1489435,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T22:11:25.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":26193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26193,"derivative":{"exercise_price":8.59,"expiration_date":"2034-06-03","underlying":"Class A Common Stock","underlying_shares":26193},"source":{"system":"sec-edgar","filing":"0001601830-24-000069","document":"wk-form4_1717625475.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000069/wk-form4_1717625475.xml","form_type":"4"}},{"id":1489434,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-05T22:11:25.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":13097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer."}],"balance_after":72186,"source":{"system":"sec-edgar","filing":"0001601830-24-000069","document":"wk-form4_1717625475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000069/wk-form4_1717625475.xml","form_type":"4"}},{"id":41500,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-02T20:17:40.000Z","date":"2024-04-30","kind":"grant","planned":false,"acquired":true,"shares":65625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027."}],"balance_after":65625,"derivative":{"exercise_price":129.22,"exercise_date":"2025-04-30","expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":65625},"source":{"system":"sec-edgar","filing":"0001127602-24-013958","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760224013958/form4.xml","form_type":"4"}},{"id":1548638,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:43:25.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":1267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":59089,"source":{"system":"sec-edgar","filing":"0001601830-24-000031","document":"wk-form4_1712180594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000031/wk-form4_1712180594.xml","form_type":"4"}},{"id":46648,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T21:03:49.000Z","date":"2024-02-09","kind":"exercise","planned":false,"acquired":false,"shares":14702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. (\"Organon\") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the \"Form 10\"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020."}],"balance_after":0,"derivative":{"exercise_price":62.07,"exercise_date":"2018-05-05","expiration_date":"2027-05-04","underlying":"Common Stock","underlying_shares":14702},"source":{"system":"sec-edgar","filing":"0001127602-24-004438","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760224004438/form4.xml","form_type":"4"}},{"id":46647,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2024-02-12T21:03:49.000Z","date":"2024-02-09","kind":"sale","planned":false,"acquired":false,"shares":14702,"price":125.4988,"value":1845083.3576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.4900 to $125.5330, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":46242.37,"source":{"system":"sec-edgar","filing":"0001127602-24-004438","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760224004438/form4.xml","form_type":"4"}},{"id":46646,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2024-02-12T21:03:49.000Z","date":"2024-02-09","kind":"exercise","planned":false,"acquired":true,"shares":14702,"price":62.07,"value":912553.14,"ownership":{"direct":true},"balance_after":60944.37,"source":{"system":"sec-edgar","filing":"0001127602-24-004438","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760224004438/form4.xml","form_type":"4"}},{"id":48115,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2024-01-24T21:10:00.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":25760,"price":119.43,"value":3076516.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":46242.37,"source":{"system":"sec-edgar","filing":"0001127602-24-002024","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760224002024/form4.xml","form_type":"4"}},{"id":1680548,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-11T23:51:54.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":962,"price":14.0282,"value":13495.1284,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14 to $14.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee."}],"balance_after":421000,"source":{"system":"sec-edgar","filing":"0001209191-24-001486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124001486/doc4.xml","form_type":"4"}},{"id":1680547,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-11T23:51:54.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":28038,"price":13.65,"value":382718.7,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price.  These shares were sold in multiple lots at prices ranging from $13 to $13.99 per share.  Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee."}],"balance_after":421962,"source":{"system":"sec-edgar","filing":"0001209191-24-001486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124001486/doc4.xml","form_type":"4"}},{"id":1686962,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-04T23:11:21.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1327618,"source":{"system":"sec-edgar","filing":"0001601830-24-000001","document":"wk-form4_1704409872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000001/wk-form4_1704409872.xml","form_type":"4"}},{"id":1764909,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-04T21:46:09.000Z","date":"2023-04-21","kind":"gift","planned":false,"acquired":false,"shares":627705,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 GRAT"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 687,295 shares transferred to the Reporting Person from the Dean Y. Li 2021 GRAT"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123052058/doc4.xml","form_type":"4"}},{"id":1764908,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-04T21:46:09.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 687,295 shares transferred to the Reporting Person from the Dean Y. Li 2021 GRAT"}],"balance_after":1326415,"source":{"system":"sec-edgar","filing":"0001209191-23-052058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123052058/doc4.xml","form_type":"4"}},{"id":1833484,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-06T22:10:02.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":637461,"source":{"system":"sec-edgar","filing":"0001209191-23-041655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123041655/doc4.xml","form_type":"4"}},{"id":1847512,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T21:23:21.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":25224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25224,"derivative":{"exercise_price":8.92,"exercise_date":"2024-06-16","expiration_date":"2033-06-16","underlying":"Class A Common Stock","underlying_shares":25224},"source":{"system":"sec-edgar","filing":"0001209191-23-038844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123038844/doc4.xml","form_type":"4"}},{"id":1847511,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-21T21:23:21.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":12612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy.  The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer."}],"balance_after":636021,"source":{"system":"sec-edgar","filing":"0001209191-23-038844","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123038844/doc4.xml","form_type":"4"}},{"id":56297,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T21:56:16.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":77455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026."}],"balance_after":77455,"derivative":{"exercise_price":117.89,"exercise_date":"2024-05-02","expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":77455},"source":{"system":"sec-edgar","filing":"0001127602-23-014553","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760223014553/form4.xml","form_type":"4"}},{"id":56368,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2023-05-03T20:10:55.000Z","date":"2023-05-01","kind":"exercise","planned":false,"acquired":false,"shares":1062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023."}],"balance_after":0,"derivative":{"exercise_date":"2021-05-01","expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":1062},"source":{"system":"sec-edgar","filing":"0001127602-23-014248","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760223014248/form4.xml","form_type":"4"}},{"id":56367,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2023-05-03T20:10:55.000Z","date":"2023-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":524,"price":115.47,"value":60506.28,"ownership":{"direct":true},"balance_after":20471.432,"source":{"system":"sec-edgar","filing":"0001127602-23-014248","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760223014248/form4.xml","form_type":"4"}},{"id":56366,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2023-05-03T20:10:55.000Z","date":"2023-05-01","kind":"exercise","planned":false,"acquired":true,"shares":1062,"price":115.47,"value":122629.14,"ownership":{"direct":true},"balance_after":20995.432,"source":{"system":"sec-edgar","filing":"0001127602-23-014248","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760223014248/form4.xml","form_type":"4"}},{"id":1924568,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-05T22:00:53.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":1724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":623409,"source":{"system":"sec-edgar","filing":"0001209191-23-023433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123023433/doc4.xml","form_type":"4"}},{"id":60023,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2023-01-25T21:59:46.000Z","date":"2023-01-23","kind":"grant","acquired":true,"shares":3275,"price":109.88,"value":359857.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":19933.432,"source":{"system":"sec-edgar","filing":"0001127602-23-002223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760223002223/form4.xml","form_type":"4"}},{"id":2061705,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-01-05T23:29:47.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":621685,"source":{"system":"sec-edgar","filing":"0001209191-23-002070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123002070/doc4.xml","form_type":"4"}},{"id":2141871,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-10-06T01:15:54.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":1092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":620112,"source":{"system":"sec-edgar","filing":"0001209191-22-052917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122052917/doc4.xml","form_type":"4"}},{"id":2211334,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-07-06T21:51:06.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":1409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":619020,"source":{"system":"sec-edgar","filing":"0001209191-22-041281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122041281/doc4.xml","form_type":"4"}},{"id":2229484,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T00:18:11.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":36290,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36290,"derivative":{"exercise_price":6.2,"exercise_date":"2023-06-14","expiration_date":"2032-06-14","underlying":"Class A Common Stock","underlying_shares":36290},"source":{"system":"sec-edgar","filing":"0001209191-22-037640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122037640/doc4.xml","form_type":"4"}},{"id":2229483,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-17T00:18:11.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":18145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy.  The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders."}],"balance_after":617611,"source":{"system":"sec-edgar","filing":"0001209191-22-037640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122037640/doc4.xml","form_type":"4"}},{"id":66591,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-05T21:11:57.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":75728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025."}],"balance_after":75728,"derivative":{"exercise_price":87.1,"exercise_date":"2023-05-03","expiration_date":"2032-05-02","underlying":"Common Stock","underlying_shares":75728},"source":{"system":"sec-edgar","filing":"0001127602-22-013527","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013527/form4.xml","form_type":"4"}},{"id":66678,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2022-05-04T21:50:31.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. (\"Organon\") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the \"Form 10\"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022."}],"balance_after":0,"derivative":{"exercise_date":"2020-05-03","expiration_date":"2022-05-03","underlying":"Common Stock","underlying_shares":773},"source":{"system":"sec-edgar","filing":"0001127602-22-013279","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013279/form4.xml","form_type":"4"}},{"id":66677,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2022-05-04T21:50:31.000Z","date":"2022-05-03","kind":"tax_withholding","acquired":false,"shares":381,"price":87.65,"value":33394.65,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":16457.945,"source":{"system":"sec-edgar","filing":"0001127602-22-013279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013279/form4.xml","form_type":"4"}},{"id":66676,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2022-05-04T21:50:31.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":773,"price":87.65,"value":67753.45,"ownership":{"direct":true},"balance_after":16838.945,"source":{"system":"sec-edgar","filing":"0001127602-22-013279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013279/form4.xml","form_type":"4"}},{"id":66800,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2022-05-03T20:21:09.000Z","date":"2022-05-01","kind":"exercise","acquired":false,"shares":1061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. (\"Organon\") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the \"Form 10\"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. (\"Organon\") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the \"Form 10\"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments."}],"balance_after":1062,"derivative":{"exercise_date":"2021-05-01","expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":1061},"source":{"system":"sec-edgar","filing":"0001127602-22-013028","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013028/form4.xml","form_type":"4"}},{"id":66799,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2022-05-03T20:21:09.000Z","date":"2022-05-01","kind":"tax_withholding","acquired":false,"shares":523,"price":88.69,"value":46384.87,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":16065.945,"source":{"system":"sec-edgar","filing":"0001127602-22-013028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013028/form4.xml","form_type":"4"}},{"id":66798,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2022-05-03T20:21:09.000Z","date":"2022-05-01","kind":"exercise","acquired":true,"shares":1061,"price":88.69,"value":94100.09,"ownership":{"direct":true},"balance_after":16588.945,"source":{"system":"sec-edgar","filing":"0001127602-22-013028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222013028/form4.xml","form_type":"4"}},{"id":2303477,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-04-05T23:21:17.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":1544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":599466,"source":{"system":"sec-edgar","filing":"0001209191-22-023302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122023302/doc4.xml","form_type":"4"}},{"id":69946,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2022-02-28T21:24:26.000Z","date":"2022-02-24","kind":"grant","acquired":true,"shares":3023,"price":73.51,"value":222220.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":15462.118,"source":{"system":"sec-edgar","filing":"0001127602-22-007019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760222007019/form4.xml","form_type":"4"}},{"id":2442784,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-06T01:46:30.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":597922,"source":{"system":"sec-edgar","filing":"0001209191-22-002060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122002060/doc4.xml","form_type":"4"}},{"id":2478544,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:21:30.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":1000,"price":21.058,"value":21058.0,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.03 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":1315000,"source":{"system":"sec-edgar","filing":"0001209191-21-068918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068918/doc4.xml","form_type":"4"}},{"id":2478543,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:21:30.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":14900,"price":20.4411,"value":304572.39,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price.  These shares were sold in multiple lots at prices ranging from $20.01 to $20.995 per share.  Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":1316000,"source":{"system":"sec-edgar","filing":"0001209191-21-068918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068918/doc4.xml","form_type":"4"}},{"id":2478542,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:17:34.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":13474,"price":20.2038,"value":272226.0012,"ownership":{"direct":false,"nature":"By Dean Y. Li  2021 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT."}],"balance_after":1330900,"source":{"system":"sec-edgar","filing":"0001209191-21-068911","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068911/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-19"}},{"id":2478541,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:17:34.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":5626,"price":20.0384,"value":112736.0384,"ownership":{"direct":false,"nature":"By Dean Y. Li  2021 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price.  These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share.  Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT."}],"balance_after":1344374,"source":{"system":"sec-edgar","filing":"0001209191-21-068911","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068911/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-19"}},{"id":2502244,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-11-19T22:40:19.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":13474,"price":20.2038,"value":272226.0012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":578163,"source":{"system":"sec-edgar","filing":"0001209191-21-065896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121065896/doc4.xml","form_type":"4"}},{"id":2502243,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-11-19T22:40:19.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":5626,"price":20.0384,"value":112736.0384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price.  These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share.  Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":591637,"source":{"system":"sec-edgar","filing":"0001209191-21-065896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121065896/doc4.xml","form_type":"4"}},{"id":2547964,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-10-06T00:24:07.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":597263,"source":{"system":"sec-edgar","filing":"0001209191-21-059736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121059736/doc4.xml","form_type":"4"}},{"id":2640470,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-06T21:00:37.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":596720,"source":{"system":"sec-edgar","filing":"0001209191-21-045552","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121045552/doc4.xml","form_type":"4"}},{"id":88492,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2021-05-06T20:55:57.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021."}],"balance_after":0,"derivative":{"exercise_date":"2019-05-04","expiration_date":"2021-05-04","underlying":"Common Stock","underlying_shares":694},"source":{"system":"sec-edgar","filing":"0001127602-21-015763","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015763/form4.xml","form_type":"4"}},{"id":88491,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-06T20:55:57.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":91837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024."}],"balance_after":91837,"derivative":{"exercise_price":75.99,"exercise_date":"2022-05-04","expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":91837},"source":{"system":"sec-edgar","filing":"0001127602-21-015763","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015763/form4.xml","form_type":"4"}},{"id":88490,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-06T20:55:57.000Z","date":"2021-05-04","kind":"tax_withholding","acquired":false,"shares":238,"price":75.98,"value":18083.24,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":12309.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015763","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015763/form4.xml","form_type":"4"}},{"id":88489,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-06T20:55:57.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":694,"price":75.98,"value":52730.12,"ownership":{"direct":true},"balance_after":12547.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015763","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015763/form4.xml","form_type":"4"}},{"id":88927,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-03","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022."}],"balance_after":750,"derivative":{"exercise_date":"2020-05-03","expiration_date":"2022-05-03","underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":88926,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Restricted Stock Unit","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-01","kind":"exercise","acquired":false,"shares":1030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023."}],"balance_after":2060,"derivative":{"exercise_date":"2021-05-01","expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":1030},"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":88925,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-03","kind":"tax_withholding","acquired":false,"shares":257,"price":74.5,"value":19146.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":11853.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":88924,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-03","kind":"exercise","acquired":true,"shares":750,"price":74.5,"value":55875.0,"ownership":{"direct":true},"balance_after":12110.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":88923,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-01","kind":"tax_withholding","acquired":false,"shares":354,"price":74.5,"value":26373.0,"ownership":{"direct":true},"balance_after":11360.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":88922,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-05-04T20:57:46.000Z","date":"2021-05-01","kind":"exercise","acquired":true,"shares":1030,"price":74.5,"value":76735.0,"ownership":{"direct":true},"balance_after":11714.914,"source":{"system":"sec-edgar","filing":"0001127602-21-015262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221015262/form4.xml","form_type":"4"}},{"id":2741588,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":32685,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Dean Li and Ruth Li Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32685},"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741587,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":22698,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Dean Li and Ruth Li Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22698},"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741586,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":27778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":27778,"derivative":{"exercise_price":18,"expiration_date":"2031-04-14","underlying":"Class A Common Stock","underlying_shares":27778},"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741585,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":27778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2031-04-14","underlying":"Common Stock","underlying_shares":27778},"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741584,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":13889,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":596390,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741583,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":13889,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741582,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":582501,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":582501,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741581,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":582501,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741580,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":1350000,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 2021 GRAT"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":1350000,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741579,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":1350000,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 2021 GRAT"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741578,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":450000,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 2021 Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":450000,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741577,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":450000,"ownership":{"direct":false,"nature":"By Dean Y. Li 2021 2021 Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741576,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":1422048,"ownership":{"direct":false,"nature":"By Dean Li and Ruth Li Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":1422048,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741575,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":1422048,"ownership":{"direct":false,"nature":"By Dean Li and Ruth Li Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2741574,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T00:06:45.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":55383,"ownership":{"direct":false,"nature":"By Dean Li and Ruth Li Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":1422048,"source":{"system":"sec-edgar","filing":"0001209191-21-028040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028040/doc4.xml","form_type":"4"}},{"id":2744713,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T23:28:50.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":27778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."}],"balance_after":27778,"derivative":{"exercise_price":18,"expiration_date":"2031-04-14","underlying":"Common Stock","underlying_shares":27778},"source":{"system":"sec-edgar","filing":"0001209191-21-027406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121027406/doc4.xml","form_type":"4"}},{"id":2744712,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-19T23:28:50.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":13889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021."}],"balance_after":596390,"source":{"system":"sec-edgar","filing":"0001209191-21-027406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121027406/doc4.xml","form_type":"4"}},{"id":92167,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":10863,"kind":"person","name":"Li Dean Y","position":1,"cik":"0001837016","reported_name":"Li Dean Y","relationship":{"officer":true,"officer_title":"Executive VP & President, MRL"}}],"security":"Common Stock","published_at":"2021-03-02T17:00:04.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":3485,"price":72.62,"value":253080.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares acquired in dividend reinvestment transactions."}],"balance_after":10655.093,"source":{"system":"sec-edgar","filing":"0001127602-21-008587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000112760221008587/form4.xml","form_type":"4"}}]}